Ping Xu

Title: **Ping Xu: Innovator in Locally-Active Anticoagulants**

Introduction

Ping Xu is a notable inventor based in St. Laurent, Canada, recognized for his significant contributions to the field of biomedicine. His innovative work primarily focuses on developing agents that can selectively target and treat conditions related to coagulation and inflammation.

Latest Patents

Ping Xu holds a patent for "Locally-active anticoagulants and anti-inflammatory agents." This patent describes a locally-activatable bivalent thrombin binding agent featuring two thrombin binding moieties that bind to non-overlapping sites on the surface of thrombin. These moieties are connected by a linker, which is a polypeptide containing 5 to 30 amino acid residues that maintains a folded state under specific environmental conditions when the binding agent is inactive. Upon a change in bulk temperature or the presence of hyper-mobile water, the linker undergoes a conformational change, transitioning from a folded to an unfolded state, which activates the binding agent.

This locally-activatable thrombin binding agent is designed for systemic administration while targeting specific sites of coagulation or inflammation. It selectively activates in areas where atherosclerotic plaques alter the local conditions, making it a promising candidate for site-specific anticoagulant, anti-thrombotic, and anti-inflammatory treatments.

Career Highlights

Ping Xu's career is marked by his association with the National Research Council of Canada, where he applies his expertise to advance research in biomedical applications. His work has significant implications for patients with conditions that require targeted therapeutic interventions.

Collaborations

Throughout his career, Xu has collaborated with esteemed colleagues, including Feng Ni and Sazzard Hossain. These partnerships contribute to the depth of research and innovation within his field, enhancing the development of new therapeutic solutions.

Conclusion

Ping Xu's contributions to the development of locally-active anticoagulants demonstrate his commitment to innovation in medicine. His patented technologies hold the potential to revolutionize treatment methodologies for coagulation and inflammation, ultimately improving patient outcomes.